APPENDIX 1
Submissions
1 Private Mental Health Consumer Carer Network
(Australia)
2 Geraldine Robertson
3 Brian Stafford
4 Chronic Illness Alliance
5 Diabetes Australia
6 National Association of People Living with HIVAIDS
7 Council of Social Service Network
8 Cancer Voices Australia
9 Consumers Health Forum of Australia
10 SANE Australia
11 iNova Pharmaceuticals (Aust) Pty Ltd
12 Research Australia
13 Mental Illness Fellowship of Australia
14 Australian Pain Management Association Inc.
15 Painaustralia Limited
16 Australian Medical Association
17 Brain Tumour Alliance Australia Incorporated
18 Cystic Fibrosis Australia
19 Deakin Health Economics, Deakin University
20 The Australian Lung Foundation
21 Hepatitis Australia
22 Osteoporosis Australia
23 Novo Nordisk
24 Breast Cancer Network Australia
25 Arthritis Australia
26 Positive Life NSW
27 Australasian College of Dermatologists
28 ACON
29 Sanofi
30 Queensland Positive People
31 Generic Medicines Industry Association
32 Joint submission from Cancer
Council Australia, the Clinical Oncological Society of Australia and the
Medical Oncology Group of Australia
33 Health Consumers' Council (WA)
34 Medical Oncology Group of Australia
35 Pfizer Australia
36 Medicines Australia
37 Janssen-Cilag Pty Ltd
38 Mundipharma Pty Ltd
39 Roche
40 Arafmi Mental Health Carers and Friends Association
(WA) Inc
41 Australian Federation of AIDS Organisations
42 Amgen Australia Pty Ltd
43 MS Australia
44 GlaxoSmithKline Australia
45 Allergan Australia Pty Ltd
46 The Department of Health and Ageing
47 AstraZeneca Australia Pty Ltd
48 Elizabeth Trapani
49 Cancer Voices NSW
50 National Seniors Australia
51 Janne Graham
52 Carol Hughes
53 Mental Health Council of Australia
54 Elizabeth Graham
55 Name withheld
56 Australian Pompe's Association
57 Matthew Peters
58 Valerie Hanrahan
59 Health Consumers NSW
60 Fabry Support Group Australia
61 The Royal Australasian College of Physicians
62 Northern Territory Government Department of Health
63 Department of Health Western Australia
64 Confidential
65 Dr Kathryn Antioch
Additional information received
1 Generic
Medicines Industry Association (GMiA), Case study – amiloride, tabled at
the Melbourne public hearing on 21 July 2011
2 Chronic
Illness Alliance, 'Prescription drug subsidies in Australia and New Zealand', Australian
Prescriber, Vol 33, No. 1, February 2010, tabled at the Melbourne public
hearing on 21 July 2011
3 Allergan
Australia, Answers to Questions on Notice taken at the Melbourne public hearing
on 21 July 2011, provided on 29 July 2011
4 Mundipharma
Australia, Answers to Questions on Notice taken at the Melbourne public hearing
on 21 July 2011 and additional information, provided on 5 August 2011
5 Janssen-Cilag
Australia, Answers to Questions on Notice taken at the Melbourne public hearing
on 21 July 2011 and additional information, provided on 5 August 2011
6 Medicines
Australia, Answers to Questions on Notice taken at the Canberra public hearing on
25 July 2011, provided on 8 August 2011
7 Pharmaceutical
Benefits Advisory Committee, Answers to Questions on Notice taken at the Canberra
public hearing on 25 July 2011, provided on 9 August 2011
8 Pfizer
Australia, Answers to Questions on Notice taken at the Melbourne public hearing
on 21 July 2011 and additional information, provided on 10 August 2011
9 Department
of Health and Ageing, Answers to Questions on Notice taken at the Canberra
public hearing on 25 July 2011, provided on 12 August 2011
Navigation: Previous Page | Contents | Next Page